4.7 Article

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Related references

Note: Only part of the references are listed.
Review Oncology

RET revisited: expanding the oncogenic portfolio

Lois M. Mulligan

NATURE REVIEWS CANCER (2014)

Article Biochemistry & Molecular Biology

KIF5B-RET fusions in lung adenocarcinoma

Takashi Kohno et al.

NATURE MEDICINE (2012)